Who Paid My Doc
Tegsedi
Drug Amyloidosis
NDC 72126-007-01
General payments
$12,651
Research payments
$0
Through program year 2023, $12,651 in general payments and $0 in research payments were reported against Tegsedi (Amyloidosis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $2,698 | 23 |
| 2022 | General | $2,705 | 104 |
| 2021 | General | $7,248 | 245 |
Breakdown
The top 5 of 23 recipients; each share is of general payments naming this product in 2023.
The top 5 of 10 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 14 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
372 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.